DTB time: group 1 (<90 minutes, n=564) and group 2 (>90 minutes, n=274), and were evaluated the outcomes. Outcome measures included in-hospital complications (all-cause death, recurrent myocardial infarction, stroke, major bleeding or access site complications that needed treatment) and major adverse cardiovascular events (MACE: all-cause death, target vessel revascularization, recurrent myocardial infarction, admission of heart failure) at 1 year.

**RESULTS** Mean follow up period was 1211 ± 750 days. In-hospital complication rate was 7.8% in group 1, and 13.5% in group 2 at initial hospitalization (P=0.012). Kaplan-Meier survival curves showed that freedom from MACE was 69.4% in group 1 and 61.9% in group 2 at 3 years (P=0.077).

**CONCLUSION** Shorter door-to-balloon time was associated with less in-hospital complications in patients with STEMI although it did not reduce long-term MACE.

**OTHER PHARMACOLOGIC AGENTS**

**TCTAP A-093**

Determinants of Self-Discontinuation of Secondary Prevention Medications by Coronary Heart Disease Outpatients: Focus on the Role of Erectile Dysfunction

Ali Yusof Nori,1 Baha Ibrahim,1 Muhamad Ali S.K. Abdul Kader,2 Mohamed Azmi Hassali,3 Rahmat Awang1

**BACKGROUND** Despite the significant benefit of evidence-based therapy in reducing the cardiovascular outcomes among ischemic heart disease patients, many discontinue certain medications (Mx) selectively.

**METHODS** This is a cross-sectional study included 187 non diabetic patients with documented coronary heart disease. The interview took place in the cardiology clinic of Penang General Hospital in Northern Malaysia using a comprehensive medication review form to detect Mx stopped by the patient, along with exploring the potential reasons. Erectile dysfunction or ED (predictor of interest) was assessed using the Malaysian version of the abridged International Index of the Erectile Function (5-IIEF). In addition to sociodemographic factors, knowledge about Mx names, errors in taking the prescribed regimen, experienced adverse drug events (ADE), and use of anti-impotence Mx data were obtained from the patient. Binary logistic regression was employed to identify the relationships with Mx discontinuation (outcome).

**RESULTS** Forty-seven patients (25.1 %) had a history of discontinuation at least once Mx without consulting their prescriber. Aspirin was stopped by 14 (7.6 %) patients, while 12 (6.4 %) and 15 (8 %) patients had a history of discontinuing beta blocker sand statins, respectively. Two patients (1.1 %) had a history of discontinuing clopidogrel.

**CONCLUSION** Although many patients did not admit ED as cause for Mx discontinuation, the majority had related it to the ADE. In addition to the need for enhancing patients’ knowledge to accurately intake of the prescribed doses, it is required to diagnose and consult about ED related complaints in order to reduce the risk for personal discontinuation of vital secondary prevention therapy.

**TCTAP A-095**

Impact of Proton Pump Inhibitor on One-Year Clinical Outcomes in Patients Underwent Percutaneous Coronary Intervention According to Dual Versus Triple Antiplatelet Agents

Sang-Ho Park,1 Seung-Woon Rha,1 Byoung Geol Choi,1 Se Yeon Choi,1 Shang-Dong Xu,12 Harris Ngow,1 Ji Bak Kim,1 Cheol Ung Choi,1 Eung Ju Kim,1 Dong Joo Oh1

**BACKGROUND** It is controversial that proton pump inhibitor (PPI) might affect clopidogrel platelet response and can be associated with major adverse cardiovascular events (MACEs) in patients (pts) undergoing percutaneous coronary intervention (PCI). Particularly impact of PPI on pts with triple antiplatelets (TAT) following PCI is largely unknown.

**METHODS** A total 3747 patients (pts) undergoing PCI from Oct 2004 to Apr 2013 from prospective PCI registry were investigated. Exclusion criteria were age of more than 80 years, cardiogenic shock, chronic kidney disease (creatinine level ≥2.0 or dialysis), in-hospital major bleeding requiring transfusion (major hematoma or retroperitoneal bleeding, gastro-intestinal bleeding), in-hospital death, and clinical follow-up loss less than 1 year after PCI. The pts were classified into dual antiplatelet therapy (DAT; aspirin+clopidogrel) and TAT (DAT+eptifibatide) according to different medication. Finally, 2326 pts was enrolled in the DAT group and 697 pts in the TAT group. Major clinical outcomes at one year were compared between the two groups.

**RESULTS** At baseline, age, gender, diabetes, hypertension, dyslipidemia, cerebrovascular accident, and current smoking were balanced between PPI user and non-PPI user group in both DAT and TAT. Not only in DAT group but also in TAT group, there was no significant differences in clinical outcomes including total death, cardiac death, myocardial infarction, revascularization, all major adverse cardiovascular event (MACE), target lesion revascularization (TLR)-MACE, target vessel revascularization (TVR)-MACE, and stent thrombosis between PPI user and non-PPI user (Table).

**CONCLUSION** In our study, chronic PPI use was not associated with adverse cardiovascular outcomes up to 1-year in Korean pts undergoing PCI regardless of DAT and TAT.

**TCTAP A-096**

The Effect of Atorvastatin on Inflammatory Response in Patients with ST Segment Elevation Myocardial Infarction Post Primary Percutaneous Coronary Intervention

Muhammad Barri Fahmi,1 Doni Firman1

**BACKGROUND** Myocardial necrosis triggers complement activation and neutrophil adhesion which is mediated by Intercellular Adhesion Molecule (ICAM). Results from ARMYDTC TAP-A-CAMS, showed that Atorvastatin continuous treatment reduced ICAM value in patients with stable angina pectoris. To date, there is no study yet which investigates the effect of acute Atorvastatin 80mg treatment in patients with ST Segment Elevation Myocardial Infarction (STEMI) post Primary Percutaneous Coronary Intervention (PPCI).

**METHODS** The primary study endpoint was ICAM levels (ng/mL) at baseline and 24 hours after PPCI. The secondary study endpoints were C-reactive protein, tumor necrosis factor, IL-6, and lymphocytes.

**RESULTS** In the STEMI population, the ICAM level at baseline and 24 hours after PPCI was 2578±1165 ng/mL and 2181±1165 ng/mL respectively (P=0.27). While the ICAM level at baseline and 24 hours after PPCI was 2578±1165 ng/mL and 2181±1165 ng/mL respectively (P=0.27). While the ICAM level at baseline and 24 hours after PPCI was 2578±1165 ng/mL and 2181±1165 ng/mL respectively (P=0.27). While the ICAM level at baseline and 24 hours after PPCI was 2578±1165 ng/mL and 2181±1165 ng/mL respectively (P=0.27). While the ICAM level at baseline and 24 hours after PPCI was 2578±1165 ng/mL and 2181±1165 ng/mL respectively (P=0.27).

**CONCLUSION** In conclusion, our study showed that acute Atorvastatin 80mg treatment in patients with STEMI could reduce ICAM levels, but not other inflammatory markers.

**Table.** Association with PPI use and clinical outcomes according to DAT and TAT

<table>
<thead>
<tr>
<th>One-year Clinical Outcomes</th>
<th>Dual antiplatelet agent (n=202)</th>
<th>Triple antiplatelet agent (n=193)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPI Use (n=202)</td>
<td>Non-PPI Use (n=193)</td>
<td>p-value*</td>
</tr>
<tr>
<td>total death, a (%)</td>
<td>3.1 (9.5)</td>
<td>2.1 (11.0)</td>
</tr>
<tr>
<td>cardiac death, a (%)</td>
<td>2.0 (11.0)</td>
<td>11.0 (10.0)</td>
</tr>
<tr>
<td>myocardial infarction, a (%)</td>
<td>4.1 (11.0)</td>
<td>25.1 (10.0)</td>
</tr>
<tr>
<td>revascularization, a (%)</td>
<td>20.4 (11.0)</td>
<td>11.0 (10.0)</td>
</tr>
<tr>
<td>TLR-MACE, a (%)</td>
<td>10.6 (11.0)</td>
<td>30.1 (10.0)</td>
</tr>
<tr>
<td>TVR-MACE, a (%)</td>
<td>29.8 (11.0)</td>
<td>31.4 (10.0)</td>
</tr>
</tbody>
</table>

* p<0.05
** DAT: dual antiplatelet; TAT: triple antiplatelet; PPI: proton pump inhibitor; TLR: target lesion revascularization; TVR: target vessel revascularization; MACE: major adverse cardiovascular events